MET exon 14 Mutations Encode a Hyperactive Kinase and Therapeutic Target in Lung Adenocarcinoma

被引：0
作者：
Peled, Nir [1 ]
Lu, Xinyuan [2 ]
Greer, John [2 ]
Wu, Wei [2 ]
Choi, Peter [3 ]
Berger, Alice [3 ]
Hann, Byron [2 ]
Meyerson, Matthew [4 ,5 ]
Collisson, Eric [2 ]
机构：
[1] Rabin Med Ctr, Tel Aviv, Israel
[2] UCSF, San Francisco, CA USA
[3] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[4] Broad Inst Harvard & Mit, Dana Farber Canc Inst, Boston, MA USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
MET; Resistance; Targeted therapy; Mouse model;
D O I：
10.1016/j.jtho.2016.11.1323
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.03b042
引用
收藏
页码：S961 / S961
页数：1
相关论文
共 50 条
  • [21] MET Exon 14 Skipping in Non-Small Cell Lung Cancer
    Heist, Rebecca S.
    Shim, Hyo Sup
    Gingipally, Shalini
    Mino-Kenudson, Mari
    Le, Long
    Gainor, Justin F.
    Zheng, Zongli
    Aryee, Martin
    Xia, Junfeng
    Jia, Peilin
    Jin, Hailing
    Zhao, Zhongming
    Pao, Gwilliam
    Engelman, Jeffrey A.
    Iafrate, A. John
    ONCOLOGIST, 2016, 21 (04) : 481 - 486
  • [22] Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation
    Jorge, Susan E.
    Schulman, Sol
    Freed, Jason A.
    VanderLaan, Paul A.
    Rangachari, Deepa
    Kobayashi, Susumu S.
    Huberman, Mark S.
    Costa, Daniel B.
    LUNG CANCER, 2015, 90 (03) : 369 - 374
  • [23] Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation A case report
    Tan, Xiang
    Dai, Lei
    Wang, Yongyong
    Liang, Guanbiao
    Yang, Nuo
    Chen, Mingwu
    MEDICINE, 2017, 96 (47)
  • [24] MAIC of OS and TRAE Comparing Capmatinib with Other MET Inhibitors for Treatment of Ansclc with MET Exon 14 Skipping Mutations
    Wu, Y-L.
    Yong, S.
    Yao, Y.
    Cheng-Zhi, Z.
    Wu, L.
    Zhao, J.
    Hu, J.
    Yin, Y.
    Lei, Y.
    Gao, X.
    Tang, M.
    Gupta, R.
    Biswas, C.
    Orfanos, P.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S651 - S652
  • [25] Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis
    Huy Gia Vuong
    An Thi Nhat Ho
    Altibi, Ahmed M. A.
    Nakazawa, Tadao
    Katoh, Ryohei
    Kondo, Tetsuo
    LUNG CANCER, 2018, 123 : 76 - 82
  • [26] The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
    Salgia, Ravi
    Sattler, Martin
    Scheele, Juergen
    Stroh, Christopher
    Felip, Enriqueta
    CANCER TREATMENT REVIEWS, 2020, 87
  • [27] EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
    He, Mai
    Capelletti, Marzia
    Nafa, Khedoudja
    Yun, Cai-Hong
    Arcila, Maria E.
    Miller, Vincent A.
    Ginsberg, Michelle S.
    Zhao, Binsheng
    Kris, Mark G.
    Eck, Michael J.
    Jaenne, Pasi A.
    Ladanyi, Marc
    Oxnard, Geoffrey R.
    CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1790 - 1797
  • [28] A profile on capmatinib in treating adult patients with metastatic NSCLC tumors with MET exon 14 skipping mutations
    Hida, Toyoaki
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2022, 7 (01): : 96 - 101
  • [29] The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
    Reungwetwattana, Thanyanan
    Liang, Ying
    Zhu, Viola
    Ou, Sai-Hong Ignatius
    LUNG CANCER, 2017, 103 : 27 - 37
  • [30] A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib
    Linda Mahjoubi
    Anas Gazzah
    Benjamin Besse
    Ludovic Lacroix
    Jean-Charles Soria
    Investigational New Drugs, 2016, 34 : 397 - 398
12345